Menu
No results found.
Weekly Share Price & Valuation Overview
Egetis Therapeutics AB (publ)
Egetis Therapeutics AB (publ), a pharmaceutical company, focuses on projects in late-stage development for the treatment of serious diseases with unmet medical needs in the orphan drug segment. The company's products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol overdose, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of monocarboxylate transporter 8 (MCT8) deficiency, a debilitating rare disease with no available treatment. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is based in Stockholm, Sweden.
- High gross margin (≥35%) suggests strong pricing power or cost control.
- Quick ratio ≥1.0 indicates obligations can be met without inventory.
- Net cash balance sheet provides flexibility for downturns and investment.
- Negative free cash flow — operations may rely on external financing.
- Market Cap Total equity value of the company (share price × shares outstanding).
- SEK 1.96B
- Enterprise Value Operating value: market cap + total debt − cash.
- SEK 1.80B
- Total Revenue (TTM) Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- SEK 46.70M
- Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.
- SEK 28.10M
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- SEK 0.14
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- -1.00
- Shares Outstanding
- 359.24M
- Float Shares
- 182.01M
- Implied Shares Outstanding
- 359.24M
- Operating Margin (TTM) Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
-5.10%
- Gross Margin (TTM) Reconciled Strong Gross profit ÷ revenue over the last twelve months (reconciled when possible).
-
60.17%
- ROA Return on assets: net income ÷ total assets.
-
-27.92%
- ROE Return on equity: net income ÷ shareholder equity.
-
-73.19%
- Revenue Growth Year-over-year revenue growth.
-
5.00%
- Quick Ratio Adequate Liquid current assets ÷ current liabilities (ex-inventory).
- 1.51
- Debt to Equity Total debt ÷ shareholder equity; leverage.
- 0.25
- Total Cash Cash and equivalents.
- SEK 272.80M
- Total Debt Short + long-term interest-bearing debt.
- SEK 106.50M
- Net Debt Net Cash Total debt − cash (negative = net cash).
- SEK -166.30M
- EBITDA & EBITDA margin suppressed (implausible vs revenue or not meaningful for financials).
- Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.